SCHEMBL5405496

SCHEMBL5405496

CNc1nc(Nc2ccc(Cl)c(Cl)c2)ncc1N1CCCNC1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 2/20 0.42
▸ ROS1 P08922 1/20 0.42
▸ BRD4 O60885 5/20 0.42
▸ STK17A Q9UEE5 2/20 0.41
▸ JAK2 O60674 2/20 0.41
▸ LRRK2 Q5S007 2/20 0.41
▸ STK17B O94768 1/20 0.41
▸ CDK4 P11802 1/20 0.40
▸ CCND1 P24385 1/20 0.40
▸ CCND2 P30279 1/20 0.40
▸ CCND3 P30281 1/20 0.40
▸ TNK2 Q07912 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ WEE1 P30291 3/20 0.39
▸ SYK P43405 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5419348 0.94 BRD4 (0.43) ALKROS1BRD4STK17AJAK2
SCHEMBL5405560 0.82 BRD4 (0.45) BRD4STK17AJAK2LRRK2STK17B
SCHEMBL5405501 0.80 STK17A (0.43) ALKBRD4STK17AJAK2LRRK2
SCHEMBL5418862 0.80 STK17A (0.42) ALKBRD4STK17AJAK2LRRK2
SCHEMBL5415299 0.75 LRRK2 (0.50) BRD4STK17AJAK2LRRK2STK17B
SCHEMBL5420252 0.73 ALK (0.41) ALKROS1LRRK2
SCHEMBL5402321 0.73 STK17A (0.55) BRD4STK17AJAK2LRRK2STK17B
SCHEMBL5408196 0.73 MEN1 (0.54) ALKROS1BRD4JAK2LRRK2
SCHEMBL5405395 0.73 LRRK2 (0.51) ALKBRD4JAK2LRRK2MEN1
SCHEMBL5413700 0.72 HDAC3 (0.43) ALKROS1HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166599-B2 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-23 — — US claimed
US-20050090486-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-04-28 — — US claimed
US-20030134838-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-17 — — US claimed
US-7166599-B2 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-23 — — US disclosed
US-20050090486-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-04-28 — — US disclosed
US-20030134838-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134838-A1 Trisubstituted pyrimidines APP, PSEN1, BACE1 ALK 3651/4885ROS1 2088/4885BRD4 3015/4885
US-20050090486-A1 Trisubstituted pyrimidines APP, BACE1, PSEN1 ALK 2986/4885ROS1 2422/4885BRD4 1419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback